March 20, 2024 02:34 PM EDT
R&D
Pharma

The Op­di­vo-Yer­voy com­bo from Bris­tol My­ers is work­ing to­ward ap­proval in first-line liv­er can­cer

Katherine Lewin

News Reporter

Bris­tol My­ers Squibb is work­ing to­ward its ninth ap­proval for its Op­di­vo-Yer­voy com­bi­na­tion, this time in the first-line set­ting for ad­vanced liv­er can­cer.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

A service from the Financial Times